Yasmin Hurd


Yasmin Hurd is the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute at Mount Sinai and is a professor of Neuroscience, Psychiatry, Pharmacology and Systems Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.

Early life and education

In the earlier years of her life, Hurd was particularly interested in how the brain works. To aid in covering her expenses for college, she decided to work in a research lab, which required her to take care of animals. This experience was one that sparked her childhood curiosity and set her on a path to a career in neuroscience research. She completed her PhD at the Karolinska Institutet in Stockholm, Sweden, where her work with micro-dialysis led to advances in neuropharmacology. She spent time as a Pharmacology Research Associate Fellow with the National Institutes of Health and Staff Fellow at the National Institute of Mental Health.

Career

Hurd's career began when she returned to her alma mater, Karolinska Institute as a faculty member for 13 years before beginning her career at Mount Sinai. At Mount Sinai, Hurd is currently the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute of Mount Sinai within the Behavioural Health System.
She is also the former director of the medical school's combined MD/PhD Medical Scientist Training Program. Additionally, Hurd sits on the Clinical Neuroendocrinology Branch, National Institute of Mental Health.
Hurd is a professor at the Icahn School of Medicine at Mount Sinai Hospital in New York City, where she studies addiction in people and animal models. Her animal research has revealed that drugs like marijuana can have profound effects on the adolescent brain, including effects that can even extend to the offspring of drug-users.
She is also a member of the National Academy of Medicine, American Society for Neuroscience, New York Academy of Sciences, and the College on Problems of Drug Dependence. Hurd's work has been cited more than 13,000 times, and she has an H-Index of 69.
Her work on the neurobiology of addiction, especially with regard to the effects of heroin and the developmental changes caused by cannabis, have been profiled in a variety of popular news sources.

Research

Hurd’s research focuses on the effects of cannabis and heroin on the brain. Her pre-clinical research is complemented with clinical laboratory investigations evaluating the therapeutic potential of medications such as the use of phytocannabinoids in the treatment of psychiatric disorders. One area of concentration has set out to address the gateway drug theory. Her research showed that CBD could be considered as a potentially significant option for treating patients recovering from opioid abuse, a finding that has received public attention.

Grants

Ongoing research grants as of 2019:
Title and No.RoleDescription
Translating CBD Treatment for Heroin Addiction; R01 DA048613, NIH/NIDACo-Principal InvestigatorA study of the neurobiological effects of CBD to reduce craving in human opioid users.
Transcriptional and epigenetic mechanisms in human heroin abuse; 2P01DA008227, NIH/NIDAProject Principal InvestigatorCharacterizing epigenetic networks in mesocorticolimbic structures underlying drug abuse in humans with complementary mechanistic studies in rodents.  
Cell Specificity of the Human Heroin Epigenome; R01 DA043247, NIH/NIDACo-Principal InvestigatorDetermining the epigenetic landscape of discrete cell populations in the prefrontal cortex of human heroin abusers.
Neurodevelopmental effects of cannabis and its epigenetic regulation; R01 DA030359, NIH/NIDAPrincipal InvestigatorStudying the effects of prenatal and adolescent cannabis exposure on the developing brain and adult brain and behavior.
Prevention of the cardiovascular medical consequences of drug overdose; R01DA037317, NIH/NIDACo-InvestigatorEvaluation of high-risk genetic polymorphisms that are predictive of drug overdose fatality; serum biomarkers that predict tissue/organ injury from drug toxicity; and prospective validation of a previously derived clinical risk tool in the Toxicology Investigators’ Consortium.

Publications

Partial list ranked by third-party citations:
A partial list of professional affiliations and committees includes:
Elected Member, National Academy of Medicine; American Society for Neuroscience; New York Academy of Sciences; The College on Problems of Drug Dependence; Vice-Chair, ACNP Minority Task Force; Editorial Board Member, Biological Psychiatry; Brain & Behavior Research Foundation, Scientific Council member; Editorial Board Member, Cannabis and Cannabinoid Research Journal; Editorial Board, National Academies’ Forum on Neuroscience and Nervous System Disorders, member and the SfN Public Education and Communication Committee.
Professional societies include:
American College Neuropsychopharmacology, Society for Neuroscience, New York Academy of Sciences, College on Problems of Drug Dependence, and the Society for Biological Psychiatry.